( April 24, 2025, 1:11 PM EDT) -- SAN FRANCISCO — Global Blood Therapeutics Inc. (GBT) and Pfizer Inc. tell a California federal court in an April 23 motion that an amended complaint alleging that Oxbryta (voxelotor), a prescription medication used for the treatment of sickle cell disease (SCD), caused a man to experience an increased rate of vaso-occlusive crises (VOCs) and to suffer a stroke should be dismissed for failure to state a claim....